Other
Combating Illicit Xylazine Act
This bill classifies xylazine—a veterinary sedative increasingly mixed into illicit street opioids—as a federal Schedule III controlled substance. The change creates federal criminal penalties for illegal trafficking and unauthorized possession, while requiring distributors to log sales through the federal drug tracking system. It also includes protections and transition periods so veterinarians, animal shelters, and wildlife managers can continue legally prescribing, buying, and using the drug for animal care without facing new registration hurdles.
People affected—The bill affects veterinarians, drug manufacturers, distributors, and individuals involved in animal control, but does not provide precise population counts.
Fiscal magnitude—no CBO estimate published
Reach52provisional · pending reviewrigor: heuristic llm
What this bill touches.
Sentencing & corrections−25Drugs & enforcement−40
Who it helps · who it burdens.
Who it helps
- Existing xylazine manufacturersExempts existing manufacturers from costly capital expenditures to meet Schedule III physical security standards, delays labeling and packaging mandates for one year, and directs agencies to expedite their applications.
- Animal owners, care facilities, and wildlife or animal-control programsExplicitly authorizes individuals, animal businesses, and government wildlife or animal-control programs to lawfully possess veterinary xylazine without requiring their own federal controlled-substance registration, provided it is dispensed by a registered veterinarian or pharmacy.
Who it burdens
- Xylazine manufacturers and distributorsPlaces xylazine under Schedule III of the Controlled Substances Act and mandates transaction reporting through ARCOS, subjecting manufacturers and distributors to federal controlled substance regulations, registration, and reporting duties.
- Veterinarians and animal health practitionersRequires practitioners who prescribe, dispense, or handle xylazine to comply with Schedule III registration, inventory, and recordkeeping rules after a 60-day transition period.
- Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA)Requires both agencies to expedite manufacturer regulatory submissions and submit initial (18-month) and updated (4-year) reports to Congress on illicit xylazine trafficking, diversion, and analogues.
- Illicit xylazine distributors and criminal offendersSubjects individuals who illicitly manufacture, distribute, or traffic xylazine to federal criminal penalties under Schedule III of the Controlled Substances Act and directs the U.S. Sentencing Commission to establish or update sentencing guidelines.